Free press releases distribution network?

Agency / Source: Sartorius Stedim Biotech S.A.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



New Sartorius Stedim BioOutsource Microsite Goes Live - Cellca’s Cell Line and Upstream Process Development Services Now Integrated - BioOutsource.com / Sartorius-Stedim.com
New Sartorius Stedim BioOutsource Microsite Goes Live

 

PRZOOM - /newswire/ - Goettingen, Germany, 2016/06/14 - Cellca’s Cell Line and Upstream Process Development Services Now Integrated - BioOutsource.com / Sartorius-Stedim.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced that its subsidiary BioOutsource (biooutsource.com) launched an updated website to spotlight Sartorius Stedim Cellca’s cell line and upstream process development services for the biopharmaceutical industry. The new microsite features insights into the technology and development services of Cellca most recently acquired by SSB. The availability of both subsidiaries’ unique range of integrated services will support biopharma companies to rapidly and cost-effectively develop their biologics and biosimilars.

The new microsite divides into four easy-to-navigate sections that explain Cellca’s unique CHO Expression Platform which comprises of Expression Vector, Host Cell Line, CHO Media System and Upstream Process Design. This structure gives a simple overview of the technical details and time-saving benefits of this robust, scalable expression platform for individual applications.

Cellca’s cell line and upstream process development services complement BioOutsource’s broad range of bioanalytical and biosafety testing, as well as pre-qualified biosimilar assays. As a result, scientists and potential customers can source all their needs for developing biologics and biosimilars from one trusted supplier. Additionally, as both Cellca and BioOutsource have been part of Sartorius Stedim Biotech since 2015, biopharma firms that need to commercialize their biologics will not only benefit from this niche expertise, but can also access Sartorius Stedim Biotech’s extensive global upstream process development capabilities to accelerate the development timeline of their biologics and biosimilars.

Gerry MacKay, Managing Director of Sartorius Stedim BioOutsource, commented: “We’re pleased to be launching our new microsite because it signals the availability of our unique integrated services. Developers of biologics and biosimilars can now go to our site to find out how to access a fully integrated pathway from cell line development and data characterization through to upstream process development. They can also discover how these services will support them to comply with regulatory standards for timely, cost-effective development of their biosimilars.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Sartorius Stedim Biotech S.A.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Sartorius Stedim BioOutsource Microsite Goes Live

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Sartorius Stedim Biotech | Cellca’s Cell
Contact: Press Office - Sartorius-Stedim.com 
+33(0)4 42 84 56 00 press[.]sartorius-stedim.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sartorius Stedim Biotech S.A. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Sartorius Stedim Biotech S.A. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  1Click Games

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today